Compare Lithium Americas Corp (LAC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Novo Nordisk A/S — how do they compare? Lithium Americas Corp trades at $3.31 (market cap $1.18B), while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 176.1× Lithium Americas Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| LAC | NVO | |
|---|---|---|
Market Cap | $1.18B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $63.98 |
52-Week Low | $2.71 | $35.29 |
Enterprise Value | $1.29B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $3.26, showing modest daily gains of 0.31%. The stock exhibits a bullish technical signal with mixed quarterly earnings performance, beating estimates twice but missing significantly in Q4 2025. Recent $175 million financing strengthens the balance sheet as Thacker Pass approaches peak construction. The company maintains negative profitability metrics with ROE at -11.35% but trades below book value at P/B of 0.88.
Investment outlook remains speculative with significant execution risk at Thacker Pass requiring substantial capital expenditures. Analyst consensus leans cautious with 47% buy ratings versus 53% holds. Positive catalysts include lithium demand growth and government support, but cash burn and dilution risks persist for equity holders amid ongoing development phase.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
